Rational Vaccines Announces a Clinical Trial to Determine Baseline Characteristics of Patients Diagnosed With Recurrent Symptomatic Herpes Simplex Type 2 (HSV-2) VirusAug 15, 2022
Rational Vaccines Herpes Simplex Type 2 (HSV-2) Therapeutic Vaccine Candidate Demonstrates Efficacy in a Therapeutic Animal StudyJul 8, 2022
Rational Vaccines Announces a Clinical Study of the Frequency of Symptomatic Herpes Simplex Type 1 and 2 (HSV-1 and HSV-2) Virus in HIV PatientsDec 14, 2021
Rational Vaccines Announces the Appointment of Kerstin Westritschnig, MD, as Chief Medical Officer (CMO)Sep 15, 2021